Delivery Order SPE2DB22D3011-SPE2DB25FQ2NG
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $12,041.74. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a $56,394.80 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's distribution...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $35,600.20 on August 29, 2025, for Dupixent 300 mg/2 mL pen auto-injectors. The contract is a firm fixed price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by September 2, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $91,743.02 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on September 2, 2025, with an ultimate completion date of September 3, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $37,116.52 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, which is not set-aside and carries firm fixed pricing, is scheduled for ultimate completion by August 29, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location in the same city....
- The Defense Logistics Agency awarded a $54,501.62 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 27, 2025, with ultimate completion by August 28, 2025. This firm fixed-price, competitively awarded contract—without set-aside designation—will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,709.46 for Dupixent 300 mg/2 ml pen injections on August 19, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply relationship with DLA. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order falls under AmerisourceBergen's comprehensive...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dupixent 300 mg/2 mL pen auto-injectors, with a firm fixed price ceiling value of $41,675.72 and completion date of August 14, 2025. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order valued at $20,305.35 to AmerisourceBergen Drug Corp for Dupixent 200 mg/1.14 ml pen injectors on August 7, 2025, with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price delivery order represents a single pharmaceutical procurement under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract carries no set-aside designation and is being performed at...
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ2NGDelivery Order
The Defense Logistics Agency awarded a $34,256.54 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on September 2, 2025, with an ultimate completion date of September 3, 2025. This firm fixed-price contract, issued under a non-competitive set-aside designation, reflects DLA's pharmaceutical procurement needs for military and federal healthcare systems. The award represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. Dupixent is a biologic medication used to treat conditions including moderate-to-severe atopic dermatitis and asthma, making this procurement consistent with DLA's mission to supply specialty pharmaceuticals supporting military healthcare operations worldwide. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania—the contract's place of performance—is a major pharmaceutical distributor serving as a critical vendor for federal medical supply needs. The company's DLA contracts demonstrate extensive capabilities in delivering a comprehensive range of pharmaceutical products across multiple therapeutic domains, from specialty medications to vaccines and medical devices. This delivery order exemplifies AmerisourceBergen's role as a primary pharmaceutical supplier within DLA's global supply chain, supporting the Defense Health Agency and other federal healthcare systems through competitively awarded, firm fixed-price delivery mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $34.3k | 9/2/25 |